Plain-English translation of NCT07594106 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , either alone or combined with other immune-boosting drugs, in people with advanced prostate cancer or clear cell kidney cancer. The goal is to help your immune system recognize and destroy cancer cells more effectively. Researchers want to find the right dose and understand how well this treatment works and what side effects it may cause.
Advanced prostate and kidney cancers are difficult to treat, especially when they stop responding to standard therapies or have spread to other parts of the body. This medication is designed to work differently than existing treatments by training your immune cells to specifically target cancer cells, offering hope for patients with limited options.
You likely qualify if…
You likely don't qualify if…
You will receive the study medication either as a single drug or in combination with one or two other medications, depending on which group you're assigned to. You'll visit the clinic regularly for infusions or injections, blood tests to measure drug levels and check for side effects, and scans to see how your cancer is responding. The study will track your health closely to determine the best dose and whether the treatment is working for your type of cancer.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States